FOLFOXIRI Plus Bevacizumab Is Associated with Superior PFS for Metastatic Colorectal Cancer

Share this content:

(ChemotherapyAdvisor) – Patients administered bevacizumab with first-line FOLFOXIRI (irinotecan + oxaliplatin + leucovorin + 5-fluorouracil [5-FU]) chemotherapy regimen (FOLFOXIRI/bev) for metastatic colorectal cancer (mCRC) experience significantly longer progression-free survival (PFS) and better response rates than those administered the bevacizumab plus FOLFIRI (irinotecan + leucovorin + 5-FU) regimen (FOLFIRI/bev) chemotherapy, according to results from the Italian randomized phase 3 TRIBE clinical trial, which were presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.

“The study met its primary endpoint: FOLFOXIRI/bev significantly increased PFS (median 9.5 vs. 11.9 months; HR, 0.72; 95% CI: 0.59-0.87;, P=0.001)” compared to FOLFIRI/bev, reported Fotios Loupakis, MD, PhD, of the Istituto Toscano Tumori in Livorno, Italy, and coauthors. “Response rate was also significantly increased (53% vs. 64%, P=0.015).”

Chemotherapy- and bevacizumab-related toxicities occurred at “the expected incidence,” they reported.

A total of 508 patients at 35 Italian cancer centers diagnosed with measurable and unresectable mCRC and no previous chemotherapy treatment for advanced disease were randomly assigned between 2008 and 2011 to receive either FOLFIRI/bev (Arm A: bev 5 mg/kg, irinotecan 180 mg/m2, I-LV 200 mg/m2, 5-FU bolus 400 mg/m2, 5-FU infusion 2,400 mg/m2 over 48 hours every 2 weeks) or FOLFOXIRI/bev (Arm B: bev 5 mg/kg, irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, I-LV 200 mg/m2, 5-FU infusion 3,200 mg/m2 over 48 hours every 2 weeks), Dr. Loupakis and colleagues reported.

“At a median follow-up of 20.9 months, 391 patients have progressed,” they reported.

Grade 3-4 toxicities included diarrhea (10% arm A; 18% arm B), thromboembolic events (7% in each study arm), vomiting (3% arm A; 4% arm B), stomatitis (4% arm A; 8% arm B), peripheral neurotoxicity (5% in arm B), neutropenia (20% arm A; 49% arm B), and febrile fneutropenia (6% arm A; 8% arm B), the authors reported.

“Deaths within 60 days were 3% [arm A] and 4% [arm B],” they noted.

The 2013 Gastrointestinal Cancers Symposium is co-sponsored by the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO).

Abstract ID: NCT00719797

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs